Ownership Summary
The institutional landscape for Indaptus Therapeutics, Inc. (NASDAQ:INDP) includes 4 filers as of the latest reporting cycle ending December 2025.
- The percentage of Indaptus Therapeutics owned by institutions changed from 3.8% in September 2025 to 6.1% in December 2025, marking a slight up trend.
- Quarterly data indicates a 3040.98% shift in institutional share volume, and the annual owner count reflects a decrease of 80.00%.
- During the quarter, 2 institutions bought more Indaptus Therapeutics shares, 1 sold shares, and 1 of the 4 total investors held their position steady.
- Collectively, institutional investors increased their stake in Indaptus Therapeutics to 32.20K shares as of December 2025, a change that is up by 31.17K shares quarter on quarter and down 606.21K shares year over year.
- The top institutional stake in Indaptus Therapeutics as of December 31, 2025 belongs to UBS Group AG, which owns 29.00K shares, or 5.46% of the company.
- Among the most significant buyers of Indaptus Therapeutics during December 2025 were UBS Group AG (28.50K), Tower Research Capital LLC (TRC) (2.68K).
- Leading sellers of Indaptus Therapeutics stock in December 2025 included BANK OF AMERICA CORP /DE/ (8).
- The top 4 institutional holders of Indaptus Therapeutics for the quarter ending December 2025 included UBS Group AG (29.00K), Tower Research Capital LLC (TRC) (3.15K), BANK OF AMERICA CORP /DE/ (25), SBI Securities Co., Ltd. (17).